Authors: Yamahara, Kenichi; Nagaya, Noritoshi

Source: Current Drug Delivery, Volume 5, Number 3, July 2008 , pp. 224-229(6)

Publisher: Bentham Science Publishers

Abstract:

Cell therapy is currently attracting growing interest as a potential new means of improving the prognosis of patients with heart failure. For practical reasons, autologous skeletal myoblasts have been the first to be tested in clinical trials, but recently cardiovascular researchers has explored many other cell types, including bone marrow cells, endothelial progenitor cells, mesenchymal stem cells, embryonic stem cells, and resident cardiac stem cells. While recent experimental studies and early-phase clinical trials seem to support the concept that cell therapy may enhance cardiac repair, many challenges remain before achieving this goal. Further studies should focus on finding the optimal donor cells for transplantation, the mechanism by which engrafted cells improve cardiac function, controlling the survival and proliferation of transplanted cells, and the development of more efficient cell delivery techniques.

Document Type: Research article

DOI: http://dx.doi.org/10.2174/156720108784911703

Publication date: 2008-07-01

More about this publication?

• The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.
  
  The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.
  
  The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Yamahara, Kenichi ;  Nagaya, Noritoshi

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers